JO
PHAT icon

John Overdeck’s Phathom Pharmaceuticals PHAT Stock Holding History

John Overdeck’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63M Buy
519,076
+36,940
+8% +$421K ﹤0.01% 2024
2026
Q1 		$5.36M Buy
482,136
+424,353
+734% +$5.36M ﹤0.01% 1929
2025
Q4 		$959K Buy
+57,783
New +$825K ﹤0.01% 2945
2025
Q2 		– Sell
-97,327
Closed -$610K – 3446
2025
Q1 		$610K Sell
97,327
-388,463
-80% -$2.36M ﹤0.01% 2435
2024
Q4 		$3.94M Buy
485,790
+331,760
+215% +$4.11M 0.01% 1252
2024
Q3 		$2.78M Sell
154,030
-149,401
-49% -$2.09M 0.01% 1468
2024
Q2 		$3.13M Sell
303,431
-164,017
-35% -$1.69M 0.01% 1255
2024
Q1 		$4.96M Buy
467,448
+200,591
+75% +$1.7M 0.01% 976
2023
Q4 		$2.44M Buy
266,857
+182,794
+217% +$1.57M 0.01% 1387
2023
Q3 		$872K Buy
84,063
+42,563
+103% +$584K ﹤0.01% 2013
2023
Q2 		$594K Buy
41,500
+12,400
+43% +$143K ﹤0.01% 2252
2023
Q1 		$208K Buy
+29,100
New +$256K ﹤0.01% 2540
2022
Q3 		– Sell
-35,304
Closed -$298K – 2727
2022
Q2 		$298K Sell
35,304
-4,912
-12% -$50.5K ﹤0.01% 2028
2022
Q1 		$547K Sell
40,216
-23,580
-37% -$381K ﹤0.01% 1976
2021
Q4 		$1.25M Buy
63,796
+41,241
+183% +$971K ﹤0.01% 2350
2021
Q3 		$724K Sell
22,555
-17,429
-44% -$579K ﹤0.01% 2924
2021
Q2 		$1.35M Sell
39,984
-14,671
-27% -$525K ﹤0.01% 2214
2021
Q1 		$2.05M Buy
+54,655
New +$2.29M 0.01% 1691

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

John Overdeck's PHAT Position: Q2 2026 in Review

John Overdeck increased its Phathom Pharmaceuticals (PHAT) stake by 7.7% in Q2 2026, buying an estimated $421K and bringing the position to 519,076 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

John Overdeck first reported a position in PHAT in Q1 2021 and has held it in 18 quarters since. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • John Overdeck held 519,076 shares of Phathom Pharmaceuticals worth $5.63M as of Q2 2026.
  • John Overdeck bought 36,940 Phathom Pharmaceuticals shares in Q2 2026, an estimated $421K.
  • Phathom Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2024 holding.
  • John Overdeck first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.